Back to News
Market Impact: 0.28
Innate Pharma Q2 Earnings Call Highlights
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Innate Pharma reported first-half 2026 clinical and business-development progress, including the closing of its strategic Sobi partnership for lacutamab. The company also completed dose-escalation enrollment for IPH4502 and completed enrollment in the PACIFIC-9 Phase III trial of monalizumab. The milestones modestly de-risk its pipeline execution, although no clinical efficacy data or financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
IPHA0.62
SOBI0.38
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Kosmos Energy stock sinks on third quarter earnings, revenue miss
- NUBURU Completes Tekne Acquisition, Adding a $93 Million Defense & Dual-Use Program Portfolio and Advancing Expansion Across NATO and Allied Markets